Biotech is back but is it any safer?

Mon Mar 1, 2004



After years in the wilderness the few surviving biotech and healthcare funds are talking of a new paradigm and say it it will be different this time

After a two-year slump, biotech is back on top again. And the recent approval of ImClone's experimental cancer drug Erbitux has given the industry another boost and persuaded many hedge fund investors to take another look at the sector, which is populated by a number of big players such as OrbiMed, Deerfield and MPM and is showing signs of spawning a series of new healthcare funds over the coming months with four or five on the launch pad.

Among the likely new entrants is Tim Bepler, a former consultant for Circle T Partners, who is incubating a healthcare fund. Bepler was the sole portfolio manager for several funds totaling $300 million at Orbitex Management, including the Orbitex Health & Biotech Fund. His new...

ISSN: 2151-1845 / CDC10004H

TAKE A FREE TRIAL

The full contents of this article are available to active AR subscribers and trialists only.

To continue reading please,
take a free trialsubscribe or log in to AR.

Subscribe

Subscribers have unlimited access to all current and archive content. Start your subscription today - click on the button below.

Subscribe now